ACTRN12623001068651RecruitingPhase 4
Evaluating the Positioning of Esketamine Treatment (PoET) for symptom management in adults with major depressive disorder
orthern Sydney Local Health District0 sites162 target enrollmentStarted: October 5, 2023Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Recruiting
- Sponsor
- Enrollment
- 162
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Non-randomised trial
- Primary Purpose
- Treatment
- Masking
- Open (masking not used)
Eligibility Criteria
- Ages
- 18 Years to 65 Years (—)
- Sex
- All
Inclusion Criteria
- •1. Be an adult aged 18-65 years old
- •2. Have a primary diagnosis of Major Depressive Disorder (MDD)
- •***Please note: a co-morbid diagnosis of an anxiety disorder or ADHD can be included***
- •3. Be currently depressed and on medication for current episode
- •4. Have experienced an inadequate response to 2 or more courses of antidepressants (of adequate dose and duration)
- •5. Be maintained on their current antidepressant medication or psychological therapy at the time of enrolment
- •6. Able to understand and able to provide informed consent
Exclusion Criteria
- •1.Concurrent diagnoses
- •-Participants with DSM-5 disorders e.g., current substance misuse disorder, bipolar disorder, schizophrenia
- •-Participants who are unable to understand the study and therefore unable to provide informed consent
- •2.Pregnancy
- •-Participants who are pregnant and/or breastfeeding
- •-Participants who are not willing to avoid pregnancy for themselves or their partners during the study by using effective birth control methods
- •3.Current medications
- •-Participants taking a total daily dose of benzodiazepines greater than the equivalent of 6mg/day of lorazepam
- •-Participants on complementary and alternative medicine therapies i.e., St John’s wort, Chinese medicines, and various herbal and homeopathic treatments
- •4.Stimulants
- •-Participants taking stimulants such as methylphenidate, amphetamine, and dextroamphetamine for a diagnosis such as ADHD can still have Esketamine provided they do not continue taking stimulants concurrently for the duration of the study.
- •-Concurrent use is excluded due to the synergistic effect with Esketamine that can cause increased blood pressure.
- •5.Medical history
- •-Participants with current or past history of seizures (uncomplicated childhood febrile seizures with no sequelae are not exclusionary)
- •-Participants with a history of uncontrolled hypertension
- •-Participants with uncontrolled diabetes mellitus
- •-Participants with aneurysmal vascular disease including thoracic and abdominal aorta, intracranial and peripheral arterial vessels, or arteriovenous malformation, intracerebral haemorrhage
- •-Participants with untreated glaucoma, current penetrating or perforating eye injury, brain injury, hypertensive encephalopathy, intrathecal therapy with ventricular shunts, or any other condition associated with increased intracranial pressure or increased intraocular pressure or planned eye surgery
- •-Participants who are currently receiving electroconvulsive therapy (ECT) or have received ECT in the past month
- •6.Substance Misuse History
- •-Participants who have ever had a substance misuse disorder involving any of the following over their lifetime: ketamine, phencyclidine (PCP), lysergic acid diethylamide (LSD), or 3,4-methylenedioxy-methamhetamine (MDMA), or other hallucinogen use history
- •-Participants with hypersensitivity to Esketamine, Ketamine, or any of the excipients
Investigators
Similar Trials
Completed
Phase 3
The effects of esketamine and treatment expectation in acute major depressive disorder:A pharmacological fMRI-studyMedical Dictionary for Regulatory Activities - 10037175Medical Dictionary for Regulatory Activities- 10081270Medical Dictionary for Regulatory Activities - 10057840DRKS00024815Phillips Universität Marburg165
Active, not recruiting
Phase 1
The effects of esketamine and treatment expectation in acute major depressive disorderTo unravel the neural correlates of the interaction between positive expectation (high/low) and single dose antidepressant treatment (verum/placebo) with esketamine in patients with major depressive disorderMedDRA version: 20.0Level: SOCClassification code 10037175Term: Psychiatric disordersSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 21.1Level: LLTClassification code 10081270Term: Major depressive disorderSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 21.1Level: PTClassification code 10057840Term: Major depressionSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2020-000784-23-DEPhilipps-Universität Marburg176
Recruiting
Phase 4
Positioning of Esketamine Treatment in the Real-world Management of DepressionMajor Depressive DisorderNCT06103760Royal North Shore Hospital162
Not yet recruiting
Phase 3
A randomised non-inferiority trial of esketamine versus electroconvulsive therapy in treatment-resistant depressiosadness10027946Treatment-resistant depressionNL-OMON51415niversitair Medisch Centrum Groningen180
Recruiting
Phase 3
RESET-TRD; a Randomised trial on oral ESketamine compared to Electroconvulsive Therapy for patients with Treatment Resistant Depressiosadness10027946Treatment-resistant depressionNL-OMON56600niversitair Medisch Centrum Groningen172